← Eichor
Study identifier: NCT05260671 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Condition: Head and Neck Neoplasms · Recurrent Disease · Metastatic Cancer  ·  Sponsor: Eye & ENT Hospital of Fudan University

PhasePhase 2
Planned participants48
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoshen Wang  ·  18917785187  ·  ruijin702@163.com

Always discuss trial participation with your own doctor first.

Locations (2)

Department of radiotherapy,The First Bethune Hospital of Jilin UniversityChangchun, Jilin, ChinaRecruiting
Department of Radiotherapy, Eye & ENT Hospital of Fudan UniversityShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05260671